Monoclonal antibody nirsevimab provides strong real-world protection against severe RSV in infants, suggests meta-analysis ...

Have you ever wondered about what became of COVID vaccine companies after the pandemic settled down? Find out in this article ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

A monoclonal antibody -- a protein created in a lab which mimics the work of a natural antibody -- could be highly effective ...

Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial virus (RSV) infections in infants, suggests a meta-analysis published in The ...

Q1 2025 Earnings Call Transcript May 1, 2025 Moderna, Inc. beats earnings expectations. Reported EPS is $-2.52, expectations ...

The Ministry of Public Health (MoPH) announced the health requirements for Hajj vaccinations for the 1446 AH (2025) season, ...

The Ministry of Public Health (MoPH) has announced the health requirements for Haj vaccinations for the 1446 AH (2025) season ...

The US Department of Health and Human Services said Thursday that it aims to accomplish within four years a scientific feat ...